1
|
Victorson D, Morgan T, Kutikov A, Novakovic K, Kundu S, Horowitz B, Jackson K, Addington E, Murphy K, Sauer C, Brendler C. Mindfulness-based stress reduction for men on active surveillance for prostate cancer and their spouses: Design and methodology of a randomized controlled trial. Contemp Clin Trials 2023; 125:107059. [PMID: 36563902 PMCID: PMC9918709 DOI: 10.1016/j.cct.2022.107059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2022] [Revised: 12/18/2022] [Accepted: 12/19/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND Although active surveillance (AS) is an increasingly adopted treatment paradigm for management of very low risk prostate cancer, many men and their partners face a variety of AS-related psychosocial stressors. Stressors may include anxiety and fear of progression, which may negatively affect short- and long-term psychosocial adjustment and influence early withdrawal from AS in order to seek definitive therapies such as surgery or radiation. Here we describe the protocol for an NCI-funded trial, which seeks to examine the efficacy of mindfulness training compared with a time/attention-matched health promotion control condition in a geographically generalizable sample of men on AS and their spouses. METHODS Using a randomized, controlled, partially double-blinded study design, this study involves the delivery of 8 weeks of standardized mindfulness training (MBSR; mindfulness-based stress reduction) and patient reported outcomes over a 12-month period (proposed enrollment of 80 men on AS and spouses), compared with a health promotion control (proposed enrollment of 80 men on AS and spouses) that has been matched for time and attention. Baseline (T1) measures (e.g., anxiety, fear of progression, quality of life) are administered just prior to randomization to the two study arms, followed by repeated assessments at 2 months (T2), 6 months (T3) and 12 months (T4). CONCLUSION This study has the potential to offer men and their partners on AS with important educational and self-regulatory skills to better cope and adjust with known stressors related to being placed on this protocol.
Collapse
Affiliation(s)
- David Victorson
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
| | - Todd Morgan
- University of Michigan, Department of Urology, Ann Arbor, MI, USA
| | | | - Kristian Novakovic
- John and Carol Walter Center for Urological Health, NorthShore University Health System, Evanston, IL, USA
| | - Shilajit Kundu
- Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Bruriah Horowitz
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Kathryn Jackson
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Elizabeth Addington
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Karly Murphy
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Christina Sauer
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Charles Brendler
- John and Carol Walter Center for Urological Health, NorthShore University Health System, Evanston, IL, USA
| |
Collapse
|
2
|
Liebers F, Brendler C. Berufliches Sitzens und Beschwerden im Muskel-Skelett-System – Auswertung auf Basis der BiBB/BAuA-Erwerbstätigenbefragung 2018. Das Gesundheitswesen 2021. [DOI: 10.1055/s-0041-1732152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- F Liebers
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA)
| | - C Brendler
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA)
| |
Collapse
|
3
|
Sauter M, Müller C, Barthelme J, Brendler C, Liebers F. Heben und Tragen schwerer Lasten als berufliche Expositionen in verschiedenen Berufsgruppen und Rückenschmerzen – Ergebnisse der BIBB/BAuA Erwerbstätigenbefragung 2018. Das Gesundheitswesen 2021. [DOI: 10.1055/s-0041-1732187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- M Sauter
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
- Berlin School of Public Health
| | - C Müller
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
- Berlin School of Public Health
| | - J Barthelme
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
- Berlin School of Public Health
| | - C Brendler
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| | - F Liebers
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| |
Collapse
|
4
|
Brendler C, Liebers F. Stehen während der Arbeit - Prävalenz von Schmerzen in den Beinen. Das Gesundheitswesen 2021. [DOI: 10.1055/s-0041-1732212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Barthelme J, Liebers F, Müller C, Sauter M, Brendler C. Körperzwangshaltungen (Arbeiten über Kopf) und deren Assoziation zu Schmerzen im Nacken-Schulter-Bereich – themenspezifische Auswertung einer Querschnittsbefragung deutscher Erwerbstätiger. Das Gesundheitswesen 2021. [DOI: 10.1055/s-0041-1732089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- J Barthelme
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| | - F Liebers
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| | - C Müller
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| | - M Sauter
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| | - C Brendler
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| |
Collapse
|
6
|
Müller C, Sauter M, Barthelme J, Brendler C, Liebers F. Assoziation zwischen Manuellen Arbeitsprozessen und Schmerzen im Bereich der Hände in der BIBB/BAuA-Erwerbstätigenbefragung 2018. Das Gesundheitswesen 2021. [DOI: 10.1055/s-0041-1732160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- C Müller
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| | - M Sauter
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| | - J Barthelme
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| | - C Brendler
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| | - F Liebers
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin
| |
Collapse
|
7
|
Brendler C, Backé EM, Latza U. Schichtarbeit, messbare frühe funktionelle Veränderungen und Herz-Kreislauf-Erkrankungen. Das Gesundheitswesen 2018. [DOI: 10.1055/s-0038-1667670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- C Brendler
- BAuA Berlin, FB Arbeit und Gesundheit, Berlin, Deutschland
| | - EM Backé
- BAuA Berlin, FB Arbeit und Gesundheit, Berlin, Deutschland
| | - U Latza
- BAuA Berlin, FB Arbeit und Gesundheit, Berlin, Deutschland
| |
Collapse
|
8
|
Gillard M, Morales A, Crawford S, Brendler C, Griend DV, Franco O. Abstract 5068: Distinct pro-inflammatory cytokines in prostate fibroblasts from African-Americans with prostate cancer increase the tumorigenicity of cancer cells. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: African-American (AA) men are disproportionately affected by prostate cancer (PCa) compared with Caucasian (CA) men. AA men have higher PCa incidence and, once diagnosed, a higher stage-specific mortality rate (2.4 times higher) than CA men. Although socioeconomic factors partially explain such differences, a growing body of new scientific evidence suggests that biological factors, such as differences at the genetic and molecular level could be more critical than previously thought for the observed racial PCa disparities in incidence and outcome. Recent gene expression studies revealed that differences in the tumor microenvironment (TME) of AA vs. CA prostate tumors could affect the immune-inflammatory milieu. Fibroblasts are important regulators of stromal-epithelial paracrine interactions (SEI) in the TME. We isolated fibroblasts from AA and CA PCa patients and compared their biological effects in vitro and in vivo on PCa cell lines.
Methods: Prostate fibroblasts were isolated from AA (PrF-AA) and CA (PrF-CA) patient tissues. Characterization of PrF included assaying their proliferation and expression of potential markers associated with the activation of carcinoma associated fibroblasts. In vitro effects of AA vs. CA fibroblasts on PCa cell proliferation and motility were studied. In vivo, the pro-tumorigenic properties of fibroblasts were tested using a subrenal xenograft model in SCID mice. RNA-Seq and cytokine array analysis of potential paracrine mediators of tumorigenesis was performed. Immunohistochemical analysis of a panel of putative stromal markers associated with racial differences was assessed in a cohort of PCa tissues from AA and CA.
Results: Prostate fibroblasts from AA vs. CA men exhibit increased proliferation in response to known stromal mitogens. Expression of markers associated with myofibroblast activation (αSMA, vimentin and Tenascin-C) were significantly elevated in AA. Interestingly, expression of the androgen receptor (AR) and activation of AR signaling was significantly increased in PrF-AA compared to PrF-CA. The paracrine effects of PrF-AA on PCa cell proliferation and motility were significantly greater compared to those induced by PrF-CA. In an in vivo model, PRF-AA induced formation of larger and more invasive tumors by the AA PCa cell line E006AA compared to PRF-CA. Analysis of downstream regulatory pathways and potential paracrine mediators identified a panel of pro-inflammatory cytokines notably interleukins (IL6, IL11, IL17, IL18BP), growth factors (VEGF, FGF, BDNF), and other mediators enriched in PRF-AA.
Conclusions: Prostate fibroblasts from African American men show enhanced secretion of pro-inflammatory and pro-proliferative mediators that can potentially increase the tumorigenicity of PCa cells through selective paracrine mechanisms.
Citation Format: Marc Gillard, Alejandro Morales, Susan Crawford, Charles Brendler, Donald Vander Griend, Omar Franco. Distinct pro-inflammatory cytokines in prostate fibroblasts from African-Americans with prostate cancer increase the tumorigenicity of cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5068.
Collapse
Affiliation(s)
| | | | | | | | | | - Omar Franco
- 2NorthShore University HealthSystem, Evanston, IL
| |
Collapse
|
9
|
Gillard M, Crawford S, Brendler C, Vander Griend D, Franco O. MP29-06 INCREASED PRO-TUMORIGENIC PROPERTIES OF PROSTATE FIBROBLASTS IN AFRICAN AMERICAN MEN COMPARED TO CAUCASIANS. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 2018; 118:e17. [PMID: 29509747 PMCID: PMC5877440 DOI: 10.1038/bjc.2018.11] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
This corrects the article DOI: 10.1038/bjc.2017.429.
Collapse
|
11
|
Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 2018; 118:266-276. [PMID: 29301143 PMCID: PMC5785754 DOI: 10.1038/bjc.2017.429] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 11/03/2017] [Accepted: 11/06/2017] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort. METHODS PSAV was calculated using logistic regression to determine if PSA or PSAV predicted the result of prostate biopsy (PB) in men with elevated PSA values. Cox regression was used to determine whether PSA or PSAV predicted PSA elevation in men with low PSAs. Interaction terms were included in the models to determine whether BRCA status influenced the predictiveness of PSA or PSAV. RESULTS 1634 participants had ⩾3 PSA readings of whom 174 underwent PB and 45 PrCas diagnosed. In men with PSA >3.0 ng ml-l, PSAV was not significantly associated with presence of cancer or high-grade disease. PSAV did not add to PSA for predicting time to an elevated PSA. When comparing BRCA1/2 carriers to non-carriers, we found a significant interaction between BRCA status and last PSA before biopsy (P=0.031) and BRCA2 status and PSAV (P=0.024). However, PSAV was not predictive of biopsy outcome in BRCA2 carriers. CONCLUSIONS PSA is more strongly predictive of PrCa in BRCA carriers than non-carriers. We did not find evidence that PSAV aids decision-making for BRCA carriers over absolute PSA value alone.
Collapse
Affiliation(s)
| | - Christina G Hutten Selkirk
- The John and Carol Walter Center for Urological Health, Department of Surgery, North Shore University Health System, Evanston, IL 60201, USA
- Center for Medical Genetics, Department of Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA
| | - Sibel Saya
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Elizabeth Bancroft
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham Rd, London SW3 6JJ, UK
| | - Emily Vertosick
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Tokhir Dadaev
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Charles Brendler
- The John and Carol Walter Center for Urological Health, Department of Surgery, North Shore University Health System, Evanston, IL 60201, USA
| | - Elizabeth Page
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Alexander Dias
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham Rd, London SW3 6JJ, UK
| | - D Gareth Evans
- Genomic Medicine, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, UK
| | - Jeanette Rothwell
- Genomic Medicine, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, UK
| | - Lovise Maehle
- Department of Medical Genetics, Oslo University Hospital, Oslo 0372, Norway
| | - Karol Axcrona
- Akershus University Hospital, Lørenskog 1478, Norway
| | - Kate Richardson
- Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, East Melbourne, VIC 3000, Australia
- The Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3010, Australia
| | - Diana Eccles
- Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton SO16 5YA, UK
- Cancer Sciences, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK
| | - Thomas Jensen
- Department of Clinical Genetics, Vejle Hospital, Vejle 7100, Denmark
| | - Palle J Osther
- Department of Clinical Genetics, Vejle Hospital, Vejle 7100, Denmark
| | - Christi J van Asperen
- Leiden University Medical Center, Department of Clinical Genetics, Leiden, ZA 2333, The Netherlands
| | - Hans Vasen
- Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, ZA 2333, The Netherlands
| | | | - Janneke Ringelberg
- Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, ZA 2333, The Netherlands
| | - Cezary Cybulski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-204, Poland
| | - Dominika Wokolorczyk
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-204, Poland
| | - Rachel Hart
- Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham B15 2TG, UK
| | - Wayne Glover
- Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham B15 2TG, UK
| | - Jimmy Lam
- Department of Urology, Repatriation General Hospital, Daw Park, SA 5041, Australia
| | - Louise Taylor
- Department of Urology, Repatriation General Hospital, Daw Park, SA 5041, Australia
| | - Monica Salinas
- Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L’Hospitalet de Llobregat, Barcelona 08908, Spain
| | - Lidia Feliubadaló
- Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L’Hospitalet de Llobregat, Barcelona 08908, Spain
| | - Rogier Oldenburg
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands
| | - Ruben Cremers
- Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands
| | - Gerald Verhaegh
- Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands
| | - Wendy A van Zelst-Stams
- Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, ZA 2333, The Netherlands
| | - Jan C Oosterwijk
- Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen 9713 GZ, The Netherlands
| | - Jackie Cook
- Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield S10 2TH, UK
| | | | - Saundra S Buys
- Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT 84103, USA
| | - Tom Conner
- Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT 84103, USA
| | - Susan Domchek
- Basser Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Jacquelyn Powers
- Basser Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Margreet GEM Ausems
- Department of Genetics, University Medical Centre Utrecht, Utrecht, CX, The Netherlands
| | - Manuel R Teixeira
- Genetics Department and Research Center, Portuguese Oncology Institute, Porto 4200-072, Portugal
- Biomedical Sciences Institute (ICBAS), Porto University, Porto 4200-072, Portugal
| | - Sofia Maia
- Genetics Department and Research Center, Portuguese Oncology Institute, Porto 4200-072, Portugal
| | - Louise Izatt
- South East Thames Genetics Service, Guy’s Hospital, London SE1 9RT, UK
| | - Rita Schmutzler
- Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne 50937, Germany
| | - Kerstin Rhiem
- Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne 50937, Germany
| | - William D Foulkes
- McGill Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada
| | - Talia Boshari
- McGill Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada
| | - Rosemarie Davidson
- Duncan Guthrie Institute of Medical Genetics, Yorkhill NHS Trust, Glasgow G38SJ, UK
| | - Marielle Ruijs
- The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands
| | | | - Lesley Andrews
- Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, NSW 2031, Australia
| | - Lisa Walker
- Churchill Hospital, Headington, Oxford OX3 7LE, UK
| | - Katie Snape
- St George’s Hospital, Tooting, London SW17 0QT, UK
| | - Alex Henderson
- Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle NE1 3BZ, UK
| | - Irene Jobson
- Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle NE1 3BZ, UK
| | - Geoffrey J Lindeman
- Parkville Familial Cancer Centre, The Royal Melbourne Hospital, Grattan St, Parkville, VIC 3050, Australia
- Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3050, Australia
- Department of Medicine, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Annelie Liljegren
- Karolinska University Hospital and Karolinska Institutet, Solna 171 77, Sweden
| | - Marion Harris
- Familial Cancer Centre, Monash Health, Clayton, VIC 3168, Australia
| | - Muriel A Adank
- VU University Medical Center, Amsterdam 1081 HV, The Netherlands
| | - Judy Kirk
- Familial Cancer Service, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia
- Centre for Cancer Research, The Westmead Institute for Medical Research, Westmead, Sydney, NSW 2155, Australia
| | - Amy Taylor
- Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
| | - Rachel Susman
- Genetic Health Queensland, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia
| | | | - Nicholas Pachter
- Genetic Services of WA, King Edward Memorial Hospital, Subiaco, WA 6008, Australia
- School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6009, Australia
| | - Allan Spigelman
- Hunter Family Cancer Service, Waratah, NSW 2298, Australia
- University of New South Wales, St Vincent’s Clinical School, NSW 2052, Australia
- The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW 2010, Australia
| | - Lucy Side
- NE Thames Regional Genetics Service, Great Ormond St Hospital & UCL Institute of Women’s Health, London WC1N 3JH, UK
| | | | | | - Carole Brewer
- Peninsular Genetics, Derriford Hospital, Plymouth PL6 8DH, UK
- Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK
| | - Neus Gadea
- High Risk and Cancer Prevention Clinic, Vall d'Hebron University Hospital, Barcelona 08035, Spain
| | - Angela F Brady
- North West Thames Regional Genetics Service, London North West Healthcare NHS Trust, London HA1 3UJ, UK
| | | | - Theo van Os
- Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
| | | | | | - Julian Barwell
- University of Leicester, Leicester LE1 7RH, UK
- University Hospitals Leicester, Leicester LE1 5WW, UK
| | - Paul A James
- Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, East Melbourne, VIC 3000, Australia
- The Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3010, Australia
- Genetic Medicine, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia
| | - Declan Murphy
- The Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3010, Australia
| | - Eitan Friedman
- Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel
- Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel
| | | | - Lynn Greenhalgh
- Cheshire and Mersey Clinical Genetics Service, Liverpool Women’s Hospital, Liverpool L8 7SS, UK
| | - Elias Obeid
- Fox Chase Cancer Center, Philadelphia, PA 19111, USA
| | - Vedang Murthy
- Tata Memorial Centre, Mumbai, Maharashtra 400012, India
| | - Lucia Copakova
- National Cancer Institute, Bratislava 83310, Slovak Republic
| | - John McGrath
- Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK
| | - Soo-Hwang Teo
- Cancer Research Initiatives Foundation, Subang Jaya Medical Centre, Subang Jaya, Selangor 47500, Darul Ehsan, Malaysia
| | - Sara Strom
- The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Karin Kast
- Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01069, Germany
- National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden 01307, Germany
- German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
| | | | - Anthony Chamberlain
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Jenny Pope
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Anna C Newlin
- Center for Medical Genetics, Department of Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA
| | - Neil Aaronson
- The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands
| | | | - Chris Bangma
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands
| | - Elena Castro
- Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid 28029, Spain
| | - David Dearnaley
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham Rd, London SW3 6JJ, UK
| | - Jorunn Eyfjord
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik 101, Iceland
| | - Alison Falconer
- Imperial College Healthcare NHS Trust, London, London W2 1NY, UK
| | | | | | - Freddie C Hamdy
- Churchill Hospital, Headington, Oxford OX3 7LE, UK
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 2JD, UK
| | - Oskar Johannsson
- Landspitali—the National University Hospital of Iceland, Reykjavik 101, Iceland
| | - Vincent Khoo
- Royal Marsden NHS Foundation Trust, Fulham Rd, London SW3 6JJ, UK
| | - Jan Lubinski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-204, Poland
| | | | - Joanne McKinley
- Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, East Melbourne, VIC 3000, Australia
| | - Kylie Shackleton
- Parkville Familial Cancer Centre, The Royal Melbourne Hospital, Grattan St, Parkville, VIC 3050, Australia
| | - Anita V Mitra
- University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK
| | - Clare Moynihan
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Gad Rennert
- CHS National Cancer Control Center, Carmel Medical Center, Haifa 3436212, Israel
| | - Mohnish Suri
- Nottingham City Hospital, Nottingham NG5 1PB, UK
| | - Karen Tricker
- Genomic Medicine, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, UK
| | - The IMPACT study collaborators91
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- The John and Carol Walter Center for Urological Health, Department of Surgery, North Shore University Health System, Evanston, IL 60201, USA
- Center for Medical Genetics, Department of Medicine, NorthShore University HealthSystem, Evanston, IL 60201, USA
- Royal Marsden NHS Foundation Trust, Fulham Rd, London SW3 6JJ, UK
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Genomic Medicine, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, UK
- Department of Medical Genetics, Oslo University Hospital, Oslo 0372, Norway
- Akershus University Hospital, Lørenskog 1478, Norway
- Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre, East Melbourne, VIC 3000, Australia
- The Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3010, Australia
- Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton SO16 5YA, UK
- Cancer Sciences, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK
- Department of Clinical Genetics, Vejle Hospital, Vejle 7100, Denmark
- Leiden University Medical Center, Department of Clinical Genetics, Leiden, ZA 2333, The Netherlands
- Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, ZA 2333, The Netherlands
- Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-204, Poland
- Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham B15 2TG, UK
- Department of Urology, Repatriation General Hospital, Daw Park, SA 5041, Australia
- Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L’Hospitalet de Llobregat, Barcelona 08908, Spain
- Department of Clinical Genetics, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands
- Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen 9713 GZ, The Netherlands
- Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield S10 2TH, UK
- Royal Hallamshire Hospital, Sheffield S10 2JF, UK
- Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT 84103, USA
- Basser Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA
- Department of Genetics, University Medical Centre Utrecht, Utrecht, CX, The Netherlands
- Genetics Department and Research Center, Portuguese Oncology Institute, Porto 4200-072, Portugal
- Biomedical Sciences Institute (ICBAS), Porto University, Porto 4200-072, Portugal
- South East Thames Genetics Service, Guy’s Hospital, London SE1 9RT, UK
- Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne, Cologne 50937, Germany
- McGill Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada
- Duncan Guthrie Institute of Medical Genetics, Yorkhill NHS Trust, Glasgow G38SJ, UK
- The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands
- Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, HX 6229, The Netherlands
- Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, NSW 2031, Australia
- Churchill Hospital, Headington, Oxford OX3 7LE, UK
- St George’s Hospital, Tooting, London SW17 0QT, UK
- Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle NE1 3BZ, UK
- Parkville Familial Cancer Centre, The Royal Melbourne Hospital, Grattan St, Parkville, VIC 3050, Australia
- Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3050, Australia
- Department of Medicine, The University of Melbourne, Parkville, VIC 3050, Australia
- Karolinska University Hospital and Karolinska Institutet, Solna 171 77, Sweden
- Familial Cancer Centre, Monash Health, Clayton, VIC 3168, Australia
- VU University Medical Center, Amsterdam 1081 HV, The Netherlands
- Familial Cancer Service, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia
- Centre for Cancer Research, The Westmead Institute for Medical Research, Westmead, Sydney, NSW 2155, Australia
- Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
- Genetic Health Queensland, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia
- The Genetic Institute, Kaplan Medical Center, Rehovot 76100, Israel
- Genetic Services of WA, King Edward Memorial Hospital, Subiaco, WA 6008, Australia
- School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6009, Australia
- Hunter Family Cancer Service, Waratah, NSW 2298, Australia
- University of New South Wales, St Vincent’s Clinical School, NSW 2052, Australia
- The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW 2010, Australia
- NE Thames Regional Genetics Service, Great Ormond St Hospital & UCL Institute of Women’s Health, London WC1N 3JH, UK
- Institute of Oncology, Ljubljana 1000, Slovenia
- Hospital de Sant Pau, Barcelona 08041, Spain
- Peninsular Genetics, Derriford Hospital, Plymouth PL6 8DH, UK
- Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK
- High Risk and Cancer Prevention Clinic, Vall d'Hebron University Hospital, Barcelona 08035, Spain
- North West Thames Regional Genetics Service, London North West Healthcare NHS Trust, London HA1 3UJ, UK
- St James’ Hospital, Dublin 8, Ireland
- Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
- St Michael’s Hospital, Bristol BS2 8EG, UK
- Landspitali—the National University Hospital of Iceland, Reykjavik 101, Iceland
- University of Leicester, Leicester LE1 7RH, UK
- University Hospitals Leicester, Leicester LE1 5WW, UK
- Genetic Medicine, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia
- Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel
- Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel
- Istituto Nazionale dei Tumori, Milano 20133, Italy
- Cheshire and Mersey Clinical Genetics Service, Liverpool Women’s Hospital, Liverpool L8 7SS, UK
- Fox Chase Cancer Center, Philadelphia, PA 19111, USA
- Tata Memorial Centre, Mumbai, Maharashtra 400012, India
- National Cancer Institute, Bratislava 83310, Slovak Republic
- Cancer Research Initiatives Foundation, Subang Jaya Medical Centre, Subang Jaya, Selangor 47500, Darul Ehsan, Malaysia
- The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
- Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01069, Germany
- National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden 01307, Germany
- German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
- Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid 28029, Spain
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik 101, Iceland
- Imperial College Healthcare NHS Trust, London, London W2 1NY, UK
- HCA Healthcare Laboratories, London WC1E 6JA, UK
- University Hospital, Umea 907 37, Sweden
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 2JD, UK
- University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK
- CHS National Cancer Control Center, Carmel Medical Center, Haifa 3436212, Israel
- Nottingham City Hospital, Nottingham NG5 1PB, UK
- The IMPACT Study Collaborators List see Appendix 1
- Centre for Cancer Prevention, Queen Mary University of London, London EC1M 6BQ
- Departments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Department of Translational Medicine, Lund University, Malmö 205 02, Sweden
| | - Sue Moss
- Centre for Cancer Prevention, Queen Mary University of London, London EC1M 6BQ
| | - Zsofia Kote-Jarai
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Andrew Vickers
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Hans Lilja
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX1 2JD, UK
- Departments of Laboratory Medicine, Surgery, and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Brian T Helfand
- The John and Carol Walter Center for Urological Health, Department of Surgery, North Shore University Health System, Evanston, IL 60201, USA
| | - Rosalind A Eeles
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham Rd, London SW3 6JJ, UK
| |
Collapse
|
12
|
Brendler C, Liebers F, Latza U. Berufsspezifische Häufigkeit der Arbeitsunfähigkeit aufgrund von Thrombose und assoziierten Venenentzündungen. Das Gesundheitswesen 2017. [DOI: 10.1055/s-0037-1605931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- C Brendler
- BAuA Berlin, Fachbereich Arbeit und Gesundheit, Berlin
| | - F Liebers
- BAuA Berlin, Fachbereich Arbeit und Gesundheit, Berlin
| | - U Latza
- BAuA Berlin, Fachbereich Arbeit und Gesundheit, Berlin
| |
Collapse
|
13
|
Na R, S. Lilly SL, Han M, Yu H, Jiang D, Shah S, Ewing C, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth Jr D, Quinn M, Humphries E, Wiley K, Isaacs S, Wu Y, Liu X, Zhang N, Wang CH, Khandekar J, Hulick P, Shevrin D, Cooney K, Shen Z, Alan A, Carter H, Carducci M, Eisenberger M, Denmeade S, McGuire M, Walsh P, Helfand B, Brendler C, Ding Q, Xu J, Isaacs W. MP57-01 GERMLINE MUTATIONS IN DNA REPAIR GENES ARE SIGNIFICANTLY ENRICHED IN LETHAL PROSTATE CANCER AND ARE ASSOCIATED WITH DISEASE SURVIVAL. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.1775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Rong Na
- Shanghai, China, People's Republic of
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Yishuo Wu
- Shanghai, China, People's Republic of
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Lapan B, Franco O, Pruitt J, Petkewicz J, Helfand B, Brendler C, Wang CH, Hayward S. MP17-02 TNFα ANTAGONISTS REDUCE INCIDENCE OF BPH IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY CONDITIONS. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.591] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Zheng SL, Na R, Han M, Novakovic K, Wiley K, Isaacs S, Partin A, McGuire M, Walsh P, Brendler C, Helfand B, Isaacs W, Xu J. CHEK2
MUTATIONS INCREASE RISK FOR PROSTATE CANCER BUT DO NOT DIFFERENTIATE RISK OF LETHAL FROM INDOLENT DISEASE. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.1573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | - Rong Na
- Shanghai, China, People's Republic of
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Victorson DE, Schuette S, Schalet BD, Kundu SD, Helfand BT, Novakovic K, Sufrin N, McGuire M, Brendler C. Factors Affecting Quality of Life at Different Intervals After Treatment of Localized Prostate Cancer: Unique Influence of Treatment Decision Making Satisfaction, Personality and Sexual Functioning. J Urol 2016; 196:1422-1428. [DOI: 10.1016/j.juro.2016.05.099] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2016] [Indexed: 01/16/2023]
Affiliation(s)
- David E. Victorson
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Stephanie Schuette
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Benjamin D. Schalet
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Shilajit D. Kundu
- Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Brian T. Helfand
- Division of Urology, NorthShore University Health System, Evanston, Illinois
| | - Kristian Novakovic
- Division of Urology, NorthShore University Health System, Evanston, Illinois
| | - Nathaniel Sufrin
- Division of Urology, NorthShore University Health System, Evanston, Illinois
| | - Michael McGuire
- Division of Urology, NorthShore University Health System, Evanston, Illinois
| | - Charles Brendler
- Division of Urology, NorthShore University Health System, Evanston, Illinois
| |
Collapse
|
17
|
Victorson D, Hankin V, Burns J, Weiland R, Maletich C, Sufrin N, Schuette S, Gutierrez B, Brendler C. Feasibility, acceptability and preliminary psychological benefits of mindfulness meditation training in a sample of men diagnosed with prostate cancer on active surveillance: results from a randomized controlled pilot trial. Psychooncology 2016; 26:1155-1163. [DOI: 10.1002/pon.4135] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2015] [Revised: 01/15/2016] [Accepted: 03/20/2016] [Indexed: 02/04/2023]
Affiliation(s)
- David Victorson
- Department of Medical Social Sciences; Northwestern University Feinberg School of Medicine; Chicago IL USA
- Osher Center for Integrative Medicine at Northwestern; Northwestern Medicine; Chicago IL USA
| | - Vered Hankin
- Department of Medical Social Sciences; Northwestern University Feinberg School of Medicine; Chicago IL USA
| | - James Burns
- Department of Medical Social Sciences; Northwestern University Feinberg School of Medicine; Chicago IL USA
| | - Rebecca Weiland
- Department of Medical Social Sciences; Northwestern University Feinberg School of Medicine; Chicago IL USA
| | - Carly Maletich
- Department of Medical Social Sciences; Northwestern University Feinberg School of Medicine; Chicago IL USA
| | | | - Stephanie Schuette
- Department of Medical Social Sciences; Northwestern University Feinberg School of Medicine; Chicago IL USA
- Osher Center for Integrative Medicine at Northwestern; Northwestern Medicine; Chicago IL USA
| | - Bruriah Gutierrez
- Department of Medical Social Sciences; Northwestern University Feinberg School of Medicine; Chicago IL USA
| | | |
Collapse
|
18
|
Jiang D, Chen H, Helfand B, Conran C, Zheng SL, Brendler C, Xu J. MP90-12
INHERITED RISK FOR OTHER TYPES OF CANCER AMONG MEN WITH OR WITHOUT PROSTATE CANCER BASED ON THE GENETIC RISK SCORE. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.2556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Victorson D, Sufrin N, Helfand BT, Novakovic KR, Pariser JJ, McGuire M, Brendler C. PD47-11 PREDICTORS OF QUALITY OF LIFE IN MEN WITH LOCALIZED PROSTATE CANCER: THE ROLE OF TREATMENT DECISION MAKING SATISFACTION, NEUROTICISM, AND SEXUAL FUNCTIONING. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.2755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Kearns J, Helfand B, Brendler C, Roy H, Wang CH, Novakovic K, Subramanian H, Zhang D, Maneval C, Backman V. MP1-20 DISTINGUISHING INDOLENT FROM AGGRESSIVE PROSTATE CANCER IN ACTIVE SURVEILLANCE USING PARTIALWAVE SPECTROSCOPY TO MEASURE NANOCYTOLOGICAL FIELD CARCINOGENESIS. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
Selkirk CG, Mikropoulos C, Saya S, Bancroft E, Dadaev T, Brendler C, Page E, Leongamornlert DA, Taylor N, Saunders EJ, Cieza-Borrela C, study collaborators TIMPACT, Moss S, Kote-Jarai Z, Helfand BT, Eeles RA. MP86-11 PROSTATE SPECIFIC ANTIGEN VELOCITY AS A PREDICTIVE BIOMARKER IN A PROSPECTIVE PROSTATE CANCER SCREENING STUDY OF MEN WITH GENETIC PREDISPOSITION. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.1920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Mikropoulos C, Selkirk C, Saya S, Bancroft E, Dadaev T, Brendler C, Saunders E, Leongamornlert D, Page E, Borrella CC, study Collaborators And Steering Group TIMPACT, Moss S, Kote-Jarai Z, Helfand B, Eeles RA. Prostate-specific antigen velocity as a predictive biomarker in a prospective prostate cancer screening study (IMPACT study). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.7_suppl.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16 Background: We retrospectively assessed the clinical application of Prostate Specific Antigen Velocity (PSA V) in the IMPACT study (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in men at higher genetic risk and controls). This is a case-control prostate cancer (PrCa) screening study for men with a known genetic predisposition to PrCa; participants with a single PSA reading above 3ng/ml are offered diagnostic TRUS prostate biopsies (PB). Methods: We calculated PSA velocity (PSA V) using all three validated methods, including the arithmetic mean, the linear regression and the first and last readings equations. Pearson chi-square test was used to compare PSA V between four genetic groups: BRCA1 carriers and BRCA1 negative controls and BRCA2 carriers and BRCA2 negative controls. Results: PSA V data were evaluated in 191 men who underwent a PB with a total of 57 PrCas diagnosed. PSA V using both a threshold of 0ng/ml/year and 0.75ng/ml/year in any of the three methods was not predictive of PrCa diagnosis in BRCA1/2 controls and BRCA1 carriers. Conversely, BRCA2 carriers with a PSA V over 0.75ng/ml/year (by linear regression) were 5 times more likely to be diagnosed with PrCa [95%CI=1.5-14; p=0.003]. Interestingly PSA V using linear regression was predictive of clinically significant tumours as defined by Gleason Score (GS) >= 7. Regardless of their genetic status, men with a PSA V over 0.75/ng/ml/year were 3 times more likely to have a clinically significant PrCa [95% CI: 1.006-11.107; p=0.045] whereas men with a BRCA2 mutation were 12 times more likely [95%CI: 1.1-98; p=0.039]. Conclusions: PSA V is an important tool for identifying which men with a BRCA2 mutation would benefit from a prostatic biopsy and could be incorporated into a predictive model, along with the total PSA value. PSA V also predicts for tumour aggressiveness regardless of genetic predisposition, but more so for those with a known high risk gene mutation. Clinical trial information: NCT00261456.
Collapse
Affiliation(s)
| | | | - Sibel Saya
- Institute of Cancer Research, London, United Kingdom
| | | | - Tokhir Dadaev
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | | | - Edward Saunders
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Daniel Leongamornlert
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Elizabeth Page
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | | | | | - Sue Moss
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom
| | - Zsofia Kote-Jarai
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | | | - Ros A. Eeles
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| |
Collapse
|
23
|
Iordanescu G, Brendler C, Crawford SE, Wyrwicz AM, Venkatasubramanian PN, Doll JA. MRS measured fatty acid composition of periprostatic adipose tissue correlates with pathological measures of prostate cancer aggressiveness. J Magn Reson Imaging 2014; 42:651-7. [PMID: 25522916 DOI: 10.1002/jmri.24824] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Accepted: 12/01/2014] [Indexed: 11/08/2022] Open
Abstract
PURPOSE To investigate the association between magnetic resonance (MR) spectroscopically measured fatty acid composition of periprostatic adipose tissue and pathological markers of prostate cancer aggressiveness. MATERIALS AND METHODS Periprostatic adipose (PPA) and subcutaneous adipose (SQA) tissue from prostate cancer patients undergoing radical prostatectomy were examined ex vivo by proton MR spectroscopy at 14.1T (n = 31). Fractions of monounsaturated, polyunsaturated, total unsaturated, and saturated fatty acids, as well as T2 relaxation times were measured from the spectra. Univariate and multivariate analyses based on receiver operating characteristic (ROC) and support vector machines (SVM) were used to evaluate the association between differential measures of fatty acid levels in the PPA and SQA tissues and Gleason score and extracapsular extension (ECE), which are pathological measures of prostate cancer aggressiveness. RESULTS Both pathological markers for aggressive prostate cancer have separable patterns in the MRS features space. The association between ECE and PPA tissue fatty acid composition is linear (area under receiver operating characteristic curve (AROC) and 95% confidence intervals [CIs]: 1.00, [1.00, 1.00]), along the Δ(fM /fS ) measure, and is marked by elevated monounsaturated and reduced saturated fatty acids in the PPA tissue relative to SQA. In contrast, the association between Gleason score and PPA tissue fatty acid composition is nonlinear (classifier AROC and 95% CIs: 0.86, [0.71, 1.00]). CONCLUSION Fatty acid composition is altered in the PPA tissue of patients with aggressive prostate cancer. Ex vivo MR spectroscopy may be a useful tool in studying the altered fatty acid metabolism in prostate cancer.
Collapse
Affiliation(s)
- Gheorghe Iordanescu
- Center for Basic M.R. Research, Department of Radiology, NorthShore University HealthSystem, Evanston, Illinois, USA
| | - Charles Brendler
- Division of Urology, Department of Surgery, NorthShore University HealthSystem, Evanston, Illinois, USA
| | - Susan E Crawford
- Department of Pathology, St. Louis University, St. Louis, Missouri, USA
| | - Alice M Wyrwicz
- Center for Basic M.R. Research, Department of Radiology, NorthShore University HealthSystem, Evanston, Illinois, USA
| | | | - Jennifer A Doll
- Department of Biomedical Sciences, University of Wisconsin at Milwaukee, Milwaukee, Wisconsin, USA
| |
Collapse
|
24
|
Roy H, Brendler C, Subramanian H, Zhang D, Maneval C, Kaul K, Helfand B, Wang C, Paterakos M, Backman V. 647: Partial wave spectroscopic nanocytology to personalize management of early stage prostate cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50567-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Xu W, Zhang Z, Yang Y, Hu Z, Wang CH, Morgan M, Wu Y, Hutten R, Xiao X, Stock S, Guise T, Prabhakar BS, Brendler C, Seth P. Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases. Mol Ther 2014; 22:1504-1517. [PMID: 24791939 DOI: 10.1038/mt.2014.80] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2014] [Accepted: 04/24/2014] [Indexed: 01/17/2023] Open
Abstract
We are interested in developing oncolytic adenoviruses for the treatment of prostate cancer (PCa) bone metastases. A key limitation of Adenovirus 5 (Ad5) is that upon systemic administration, it produces major liver and systemic toxicities. To address this issue, a chimaeric Ad5/48 adenovirus mHAd.sTβRFc was created. Seven hypervariable regions of Ad5 hexon present in Ad5-based Ad.sTβRFc expressing soluble transforming growth factor beta receptor II-Fc fusion protein (sTGβRIIFc), were replaced by those of Ad48. mHAd.sTβRFc, like Ad.sTβRFc, was replication competent in the human PCa cells, and produced high levels of sTGβRIIFc expression. Compared to Ad.sTβRFc, the systemic delivery of mHAd.sTβRFc in nude mice resulted in much reduced systemic toxicity, and reduced liver sequestration. Ad.sTβRFc produced significant liver necrosis, and increases in alanine transaminase, aspartate transaminase, lactate dehydrogenase, tumor necrosis factor-α, and interleukin-6 levels, while mHAd.sTβRFc produced much reduced responses of these markers. Intravenous delivery of Ad.sTβRFc or mHAd.sTβRFc (5 × 10(10) viral particles/mouse) in nude mice bearing PC-3-luc PCa bone metastases produced inhibition of bone metastases. Moreover, a larger dose of the mHAd.sTβRFc (4 × 10(11) viral particles /mouse) was also effective in inhibiting bone metastases. Thus, mHAd.sTβRFc could be developed for the treatment of PCa bone metastases.
Collapse
Affiliation(s)
- Weidong Xu
- Gene Therapy Program, Department of Medicine, NorthShore Research Institute, Evanston, Illinois, USA
| | - Zhenwei Zhang
- Gene Therapy Program, Department of Medicine, NorthShore Research Institute, Evanston, Illinois, USA
| | - Yuefeng Yang
- Gene Therapy Program, Department of Medicine, NorthShore Research Institute, Evanston, Illinois, USA
| | - Zebin Hu
- Gene Therapy Program, Department of Medicine, NorthShore Research Institute, Evanston, Illinois, USA
| | - Chi-Hsiung Wang
- Gene Therapy Program, Department of Surgery, NorthShore Research Institute, Evanston, Illinois, USA
| | - Melanie Morgan
- Gene Therapy Program, Department of Pathology, NorthShore Research Institute, Evanston, Illinois, USA
| | - Ying Wu
- Image Processing Lab, Center for Advanced Imaging, Department of Radiology, NorthShore Research Institute, Evanston, Illinois, USA
| | - Ryan Hutten
- Image Processing Lab, Center for Advanced Imaging, Department of Radiology, NorthShore Research Institute, Evanston, Illinois, USA
| | - Xianghui Xiao
- Advanced Photon Source, Argonne National Laboratory, Argonne, Illinois, USA
| | - Stuart Stock
- Department of Molecular Pharmacology and Biological Chemistry, Northwestern University, Chicago, Illinois, USA
| | - Theresa Guise
- Department of Medicine, Indiana University, Indianapolis, Indiana, USA
| | - Bellur S Prabhakar
- Department of Microbiology and Immunology, University of Illinois, Chicago, Illinois, USA
| | - Charles Brendler
- Gene Therapy Program, Department of Surgery, NorthShore Research Institute, Evanston, Illinois, USA
| | - Prem Seth
- Gene Therapy Program, Department of Medicine, NorthShore Research Institute, Evanston, Illinois, USA.
| |
Collapse
|
26
|
Selkirk C, Hatcher D, Powers J, Hulick P, McGuire M, Brendler C, Helfand BT. MP69-05 PSA VALUES AND KINETICS OF
BRCA1
AND
BRCA2
MUTATION CARRIERS AT HIGH RISK FOR PROSTATE CANCER. J Urol 2014. [DOI: 10.1016/j.juro.2014.02.2224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Hatcher D, Wang CH, Novakovic KR, Brendler C, McGuire M, Victorson D, Helfand BT. PD21-06 THE ROLE OF AGE AND PROSTATE CANCER ANXIETY ON URINARY SYMPTOMS IN MEN ON ACTIVE SURVEILLANCE. J Urol 2014. [DOI: 10.1016/j.juro.2014.02.1683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Lee C, Zhang Q, Kozlowski J, Brendler C, Soares M, Dash A, McClelland M, Mercola D. Natural Products and Transforming Growth Factor-beta (TGF-β) Signaling in Cancer Development and Progression. Curr Cancer Drug Targets 2013; 13:500-5. [DOI: 10.2174/15680096113139990034] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2012] [Revised: 05/17/2012] [Accepted: 05/29/2012] [Indexed: 11/22/2022]
|
29
|
Cohn J, Lakeman J, Brown E, Silverstein J, Brendler C, McGuire M, Helfand B. 1245 THE IMMEDIATE IMPACT OF US PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS ON PSA SCREENING BEHAVIORS OF PRIMARY CARE PHYSICIANS. J Urol 2013. [DOI: 10.1016/j.juro.2013.02.2599] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Novakovic K, Quinn M, Fitchev P, Cornwell M, Brendler C, McGuire M, Helfand B, Pruitt J, Rabbitt S, Plunkett B, Doll J, Lee C, Crawford S. 787 SHARED LIPID ENERGY: PROSTATE CANCER CELLS STIMULATE ADIPOCYTE MIGRATION
IN VITRO
AND
IN VIVO. J Urol 2013. [DOI: 10.1016/j.juro.2013.02.351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Albaugh J, Helfand B, Victorson D, Novakovic K, Brendler C, Pruitt J, Rabbitt S, McGuire M. 1396 WHAT PREDICTS LONG TERM SEXUAL DYSFUNCTION FOR MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER? J Urol 2013. [DOI: 10.1016/j.juro.2013.02.2750] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Brendler C, Liebers F, Latza U. Berufsgruppen- und altersabhängige Unterschiede in der Arbeitsunfähigkeit durch häufige Herz-Kreislauf-Erkrankungen am Beispiel der essenziellen Hypertonie und des akuten Myokardinfarktes. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56:381-90. [DOI: 10.1007/s00103-012-1643-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Brendler C, Riebe D, Ritschel T, Beitz T, Löhmannsröben HG. Investigation of neuroleptics and other aromatic compounds by laser-based ion mobility mass spectrometry. Anal Bioanal Chem 2013; 405:7019-29. [DOI: 10.1007/s00216-012-6654-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2012] [Revised: 12/07/2012] [Accepted: 12/11/2012] [Indexed: 11/28/2022]
|
34
|
Brendler C, Pour Aryan N, Rieger V, Klinger S, Rothermel A. A Substrate Isolated LDO for an Inductively Powered Retinal Implant. BIOMED ENG-BIOMED TE 2013; 58 Suppl 1:/j/bmte.2013.58.issue-s1-O/bmt-2013-4367/bmt-2013-4367.xml. [DOI: 10.1515/bmt-2013-4367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
35
|
Shikanov S, Marchetti P, Desai V, Razmaria A, Antic T, Al-Ahmadie H, Zagaja G, Eggener S, Brendler C, Shalhav A. Short (≤1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int 2012; 111:559-63. [DOI: 10.1111/j.1464-410x.2012.11340.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- Sergey Shikanov
- Department of Surgery; University of Chicago Hospitals; Chicago; IL
| | - Pablo Marchetti
- Department of Surgery; University of Chicago Hospitals; Chicago; IL
| | - Vikas Desai
- Department of Surgery; University of Chicago Hospitals; Chicago; IL
| | - Aria Razmaria
- Department of Surgery; University of Chicago Hospitals; Chicago; IL
| | - Tatjana Antic
- Department of Surgery; University of Chicago Hospitals; Chicago; IL
| | - Hikmat Al-Ahmadie
- Department of Pathology; Sloan-Kettering Cancer Center; New York; NY; USA
| | - Gregory Zagaja
- Department of Surgery; University of Chicago Hospitals; Chicago; IL
| | - Scott Eggener
- Department of Surgery; University of Chicago Hospitals; Chicago; IL
| | - Charles Brendler
- Department of Surgery; University of Chicago Hospitals; Chicago; IL
| | - Arieh Shalhav
- Department of Surgery; University of Chicago Hospitals; Chicago; IL
| |
Collapse
|
36
|
Morgan G, Brendler C, Doll J, Fitchev P, Cornwell M, Crawford S, Plunkett B. 1319 A LIPID-ENRICHED MICROENVIRONMENT IN PROSTATE CANCER IS A POTENT STIMULATOR OF ANGIOGENESIS. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.1666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
37
|
Victorson D, Du H, Hankin V, King K, McCurdy M, Pruitt J, Rabitt S, Dangle P, Novakovic K, McGuire M, Brendler C. 384 MINDFULNESS BASED STRESS REDUCTION DECREASES FEAR OF PROGRESSION OVER TIME FOR MEN WITH PROSTATE CANCER ON ACTIVE SURVEILLANCE RESULTS FROM A RANDOMIZED CLINICAL TRIAL. J Urol 2012. [DOI: 10.1016/j.juro.2012.02.447] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
38
|
Liebers F, Brendler C, Latza U. [Causal graph (directed acyclic graph - DAG) of a secondary data analysis regarding sickness absence due to musculoskeletal disorders]. Gesundheitswesen 2011; 73:918-20. [PMID: 22193907 DOI: 10.1055/s-0031-1291191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Affiliation(s)
- F Liebers
- Bundesanstalt für Arbeitsschutz und Arbeitsmedizin/Berlin, Berlin.
| | | | | |
Collapse
|
39
|
Hardt J, Brendler C, Greiser KH, Timmer A, Seidler A, Weikert C, Latza U. [Directed acyclic graphs (DAGs) - basic concepts and application of an approach for causal analyses in epidemiology]. Gesundheitswesen 2011; 73:878-9. [PMID: 22193895 DOI: 10.1055/s-0031-1287844] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
40
|
Zhang Q, Chen L, Helfand BT, Jang TL, Sharma V, Kozlowski J, Kuzel TM, Zhu LJ, Yang XJ, Javonovic B, Guo Y, Lonning S, Harper J, Teicher BA, Brendler C, Yu N, Catalona WJ, Lee C. TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. PLoS One 2011; 6:e25168. [PMID: 21980391 PMCID: PMC3184137 DOI: 10.1371/journal.pone.0025168] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Accepted: 08/26/2011] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND DNA methyltransferase (DNMT) is one of the major factors mediating the methylation of cancer related genes such as TGF-β receptors (TβRs). This in turn may result in a loss of sensitivity to physiologic levels of TGF-β in aggressive prostate cancer (CaP). The specific mechanisms of DNMT's role in CaP remain undetermined. In this study, we describe the mechanism of TGF-β-mediated DNMT in CaP and its association with clinical outcomes following radical prostatectomy. METHODOLOGY/PRINCIPAL FINDINGS We used human CaP cell lines with varying degrees of invasive capability to describe how TGF-β mediates the expression of DNMT in CaP, and its effects on methylation status of TGF-β receptors and the invasive capability of CaP in vitro and in vivo. Furthermore, we determined the association between DNMT expression and clinical outcome after radical prostatectomy. We found that more aggressive CaP cells had significantly higher TGF-β levels, increased expression of DNMT, but reduced TβRs when compared to benign prostate cells and less aggressive prostate cancer cells. Blockade of TGF-β signaling or ERK activation (p-ERK) was associated with a dramatic decrease in the expression of DNMT, which results in a coincident increase in the expression of TβRs. Blockade of either TGF-β signaling or DNMT dramatically decreased the invasive capabilities of CaP. Inhibition of TGF-β in an TRAMP-C2 CaP model in C57BL/6 mice using 1D11 was associated with downregulation of DNMTs and p-ERK and impairment in tumor growth. Finally, independent of Gleason grade, increased DNMT1 expression was associated with biochemical recurrence following surgical treatment for prostate cancer. CONCLUSIONS AND SIGNIFICANCE Our findings demonstrate that CaP derived TGF-β may induce the expression of DNMTs in CaP which is associated with methylation of its receptors and the aggressive potential of CaP. In addition, DNMTs is an independent predictor for disease recurrence after prostatectomy, and may have clinical implications for CaP prognostication and therapy.
Collapse
Affiliation(s)
- Qiang Zhang
- Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Noack M, Brendler C, Liebers F, Walzer C, Latza U. Aufbau eines computergestützten Verfahrens zur Kodierung von Berufsangaben und Möglichkeiten zur Weiterentwicklung. Gesundheitswesen 2011. [DOI: 10.1055/s-0031-1283575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
42
|
Schumacher MC, Laven B, Petersson F, Cederholm T, Onelöv E, Ekman P, Brendler C. A comparative study of tissue ω-6 and ω-3 polyunsaturated fatty acids (PUFA) in benign and malignant pathologic stage pT2a radical prostatectomy specimens. Urol Oncol 2011; 31:318-24. [PMID: 21414816 DOI: 10.1016/j.urolonc.2011.01.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Revised: 01/21/2011] [Accepted: 01/24/2011] [Indexed: 01/30/2023]
Abstract
OBJECTIVE To analyze different polyunsaturated fatty acid (PUFA) tissue levels in malignant compared with benign prostatic tissue from the same prostate specimens. MATERIALS AND METHODS Fresh frozen benign and malignant prostatic tissue was obtained from radical prostatectomy specimens in 49 men with pathologic stage pT2a prostate cancer. Histopathologic examination confirmed that all tissues from each prostate being analyzed were either completely benign or almost totally malignant. The PUFA composition in these tissues was determined by gas-liquid chromatography on a capillary column. The relative amount of each PUFA (% of total fatty acids) was quantified by integrating the area under the peak and dividing the result by the total area of all fatty acids. RESULTS Tissue levels of dihomo-γ-linolenic acid, (C20:3w6), an ω-6 PUFA and a major precursor of ω-6 PUFA metabolites, were significantly higher in malignant compared with benign tissues (P = 0.002). Tissue levels of the downstream ω-6 metabolites, arachidonic acid (AA) (20:4ω6), and adrenic acid, (22:4ω6), were significantly lower in cancer tissues, (P < 0.0001 and P = 0.013, respectively). Overall, the total levels of ω-6 PUFA were lower in cancer (P = 0.001). CONCLUSION We found that the ω-6 PUFA AA and adrenic acid are decreased in malignant prostatic tissues compared with benign tissues from the same prostates. These findings provide additional evidence that dietary fat is associated with prostatic carcinogenesis.
Collapse
Affiliation(s)
- Martin C Schumacher
- Department of Molecular Medicine and Surgery, Karolinska Institutet Department of Urology, Stockholm, Sweden.
| | | | | | | | | | | | | |
Collapse
|
43
|
Zhang Q, Helfand B, Chen L, Zhang W, Qin W, Brendler C, Jiang T, Kundu SD, Lee B, Sharma V, Zhu L, Jovanovic B, Yang XJ, Kuzel TM, Guo Y, Lee C. 274 TGF-β MEDIATES METHYLATION OF ITS RECEPTORS PROMOTER BY ACTIVATION OF DNA METHYLTRANSFERASE (DNMT) IN PROSTATE CANCER CELLS. J Urol 2011. [DOI: 10.1016/j.juro.2011.02.366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Zhang Q, Helfand B, Chen L, Qin W, Zhang W, Brendler C, Jiang T, Kundu SD, Zhu L, Sharma V, Randall-London S, Lee B, Kuzel TM, Yang XJ, Jovanovic B, Guo Y, Kozlowski J, Lee C. 275 ANTI-TRANSFORMING GROWTH FACTOR-β ANTIBODY 1D11 SUPPRESSES THE INVASION OF HUMAN PROSTATE CANCER CELLS. J Urol 2011. [DOI: 10.1016/j.juro.2011.02.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
45
|
Chen L, Zhang Q, Helfand B, Sharma V, Qin W, Brendler C, Zhu L, Kundu SD, Jiang T, Zhang W, Lee B, Randall-London S, Jovanovic B, Yang XJ, Kozlowski J, Kuzel TM, Guo Y, Lee C. 417 5-AZA-2'-DEOXYCYTIDINE IS A POTENTIAL INHIBITOR OF HUMAN PROSTATE CANCER INVASION. J Urol 2011. [DOI: 10.1016/j.juro.2011.02.506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Liebers F, Brendler C, Walzer C, Latza U. Sekundärdatenauswertung zur berufsbezogenen Arbeitsunfähigkeit durch degenerative Muskel-Skelett-Erkrankungen für das Jahr 2008 in Deutschland. Gesundheitswesen 2010. [DOI: 10.1055/s-0030-1266505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
47
|
Brendler C, Liebers F, Walzer C, Latza U. Berufsbezogene Analyse der Arbeitsunfähigkeit aufgrund von Herz-Kreislauf-Erkrankungen für das Jahr 2008 in Deutschland. Gesundheitswesen 2010. [DOI: 10.1055/s-0030-1266523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
48
|
Hu Z, Gupta J, Zhang Z, Brendler C, Seth P. 390 ONCOLYTIC ADENOVIRUS TARGETING TRANSFORMING GROWTH FACTOR BETA SIGNALING: A NOVEL GENE THERAPY APPROACH FOR THE TREATMENT OF PROSTATE CANCER METASTASES. J Urol 2010. [DOI: 10.1016/j.juro.2010.02.458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Orvieto M, Shikanov S, Zagaja G, Brendler C, Shalhav A, Zorn K. MP-3.11: Pathological Gleason Score Trends in Patients Undergoing Radical Prostatectomy. Urology 2008. [DOI: 10.1016/j.urology.2008.08.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Orvieto M, Bernstein A, Zagaja G, Zorn K, Shalhav A, Shikanov S, Brendler C. MP-6.03: The University of Chicago Technique for Pelvic Lymphadenectomy During Robotic Prostatectomy: Assessing Nodal Yield, Operative Statistics, and Complications. Urology 2008. [DOI: 10.1016/j.urology.2008.08.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|